Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 111 posts found.

abbvie

AbbVie pays $595m upfront for experimental Boehringer psoriasis drug

March 8, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, BI 655066, Boehringer Ingelheim, psoriasis

AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer …

News
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

News
boehringer_good

Boehringer’s OFEV slows IPF disease progression by half in trials

February 26, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …

News
Jardiance

FDA reviews Jardiance as cardiovascular diabetes treatment

January 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …

News
Dr Andreas Barner

Boehringer Ingelheim invests in Europe

December 24, 2015
Manufacturing and Production, Sales and Marketing Austria, Biberach, Boehringer Ingelheim, Vienna, biologicals, manufacturing, production

Boehringer Ingelheim will kick off its pharma investments in 2016 with a half a billion Euro outlay and plans to …

News
FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …

News
Sanofi BI logos

Pharma giants Sanofi and Boehringer negotiate deal to swap assets

December 15, 2015
Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt

Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …

News
BI building

Boehringer cuts R&D budget to €11bn to focus on collaborations

November 13, 2015
Medical Communications, Research and Development Boehringer Ingelheim

Boehringer Ingelheim has launched its new research and development strategy, committing €11 billion to R&D over the next five years. …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News
BI building at night

FDA approves Boehringer’s Pradaxa reversal agent

October 19, 2015
Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab

The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …

News
BI building

Boehringer and BioMed X crowdsource top scientists to fight COPD

September 23, 2015
Research and Development Boehringer Ingelheim, COPD

Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …

News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

News
ofev1

Boehringer earns NICE nod for IPF drug Ofev

September 14, 2015
Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis

NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …

News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …

News
Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024